GZYK(SZ:002524)2022-10-28 16:00Financial Performance - The company's operating revenue for Q1 2022 was ¥186,164,288.40, representing a decrease of 2.91% compared to the same period last year[3]. - The net profit attributable to shareholders was -¥36,074,792.53, a decline of 189.14% year-over-year[3]. - The basic and diluted earnings per share were both -¥0.07, reflecting a decrease of 187.50% year-over-year[3]. - The weighted average return on equity was -11.42%, a decline of 23.14% compared to the previous year[3]. - Net loss for Q1 2022 amounted to CNY -35,990,985.53, compared to a net profit of CNY 40,022,420.82 in the same period last year[20]. - Total operating revenue for Q1 2022 was CNY 186,164,288.40, a decrease from CNY 191,740,938.17 in the previous period[19]. - Total operating costs for Q1 2022 were CNY 221,611,773.81, slightly down from CNY 224,617,270.22 in the previous period[19]. Cash Flow and Liquidity - The net cash flow from operating activities improved to ¥644,464.97, a significant increase of 103.74% compared to the previous year[3]. - The net cash flow from operating activities for the current period is ¥644,464.97, a significant improvement compared to a net outflow of ¥17,239,416.56 in the previous period[22]. - Total cash inflow from operating activities increased to ¥258,314,216.72 from ¥215,039,063.49, representing a growth of approximately 20.1%[22]. - Cash outflow for purchasing goods and services rose to ¥140,135,607.64 from ¥88,700,235.93, indicating an increase of about 58.2%[22]. - The company reported a cash inflow of ¥31,139,852.89 for the current period, compared to a cash outflow of ¥29,414,699.46 in the previous period[24]. - Cash received from the recovery of investments was ¥46,000,000.00, a significant increase from ¥1,670,000.00 in the previous period[22]. - The total cash and cash equivalents at the end of the period amounted to ¥76,161,372.41, slightly down from ¥78,837,765.50 in the previous period[24]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,792,964,699.87, down 1.96% from the end of the previous year[4]. - Total liabilities for Q1 2022 were CNY 1,485,933,923.58, compared to CNY 1,487,473,228.26 in the previous period[18]. - The company's equity attributable to shareholders decreased by 10.11% to ¥306,109,049.61 compared to the previous year[4]. - Total assets as of Q1 2022 were CNY 1,792,964,699.87, a slight decrease from CNY 1,828,855,610.04 in the previous period[18]. - The company’s total non-current liabilities increased to CNY 556,492,292.73 from CNY 507,247,678.22, an increase of 9.7%[18]. Investments and Shareholder Information - The company invested ¥10 million in acquiring equity in Suzhou Ear, Nose, and Throat Hospital Co., Ltd.[14]. - The company completed the establishment of Shanghai Guangzheng New Vision Eye Hospital Co., Ltd.[13]. - The total number of common shareholders at the end of the reporting period is 49,731[11]. - The largest shareholder, Guangzheng Investment Co., Ltd., holds 25.06% of shares, totaling 129,168,708 shares, with 66,249,700 shares pledged[12]. - The total number of restricted stock repurchased and canceled is 1,001,800 shares, reducing the total share capital from 516,368,220 shares to 515,366,420 shares[14]. - The company has no known concerted action relationships among the top shareholders[12]. Inventory and Receivables - Accounts receivable decreased to ¥74,372,646.26 from ¥100,358,869.20, a decline of about 26%[16]. - Inventory increased to ¥71,381,704.05 from ¥53,229,048.92, reflecting a growth of approximately 34.1%[16]. - The company experienced a 37.08% increase in prepayments, totaling ¥17,847,376.50, attributed to higher advance payments for goods[8]. Employee Compensation and Expenses - The company paid ¥61,074,861.34 in employee compensation, up from ¥54,472,992.21, an increase of approximately 12.0%[22]. - The company reported a significant increase in sales expenses, which rose to CNY 36,664,945.61 from CNY 48,890,770.46, a decrease of 25.0%[19].